chloroquine has been researched along with Diathesis in 14 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Between 1998 and 2001, Kenya, Uganda, Tanzania, Zanzibar, Rwanda and Burundi changed antimalarial drug policy, in the face of widespread chloroquine resistance." | 7.72 | The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. ( , 2003) |
| "Fluconazole alone was not found significantly effective against C." | 5.32 | Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole. ( Jabeen, R; Khan, MA; Mohammad, O, 2004) |
| "Between 1998 and 2001, Kenya, Uganda, Tanzania, Zanzibar, Rwanda and Burundi changed antimalarial drug policy, in the face of widespread chloroquine resistance." | 3.72 | The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. ( , 2003) |
| "To evaluate the susceptibility to coronavirus disease 2019 (COVID-19) in patients with autoimmune conditions treated with antimalarials in a population-based study." | 1.62 | Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. ( Bajocchi, G; Boiardi, L; Carrozzi, G; Cassone, G; Costantini, M; Croci, S; Galli, E; Giorgi Rossi, P; Gradellini, F; Mancuso, P; Marata, AM; Muratore, F; Pandolfi, P; Pipitone, N; Reta, M; Salvarani, C; Sandri, G; Viani, N, 2021) |
| "Fluconazole alone was not found significantly effective against C." | 1.32 | Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole. ( Jabeen, R; Khan, MA; Mohammad, O, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, X | 1 |
| Jiang, Y | 1 |
| Zhao, Y | 1 |
| Xi, H | 1 |
| Liu, C | 1 |
| Qu, F | 1 |
| Feng, X | 1 |
| Osama El-Gendy, A | 1 |
| Saeed, H | 1 |
| Ali, AMA | 1 |
| Zawbaa, HM | 1 |
| Gomaa, D | 1 |
| Harb, HS | 1 |
| Madney, YM | 1 |
| Osama, H | 1 |
| Abdelrahman, MA | 1 |
| Abdelrahim, MEA | 1 |
| Salvarani, C | 1 |
| Mancuso, P | 1 |
| Gradellini, F | 1 |
| Viani, N | 1 |
| Pandolfi, P | 1 |
| Reta, M | 1 |
| Carrozzi, G | 1 |
| Sandri, G | 1 |
| Bajocchi, G | 1 |
| Galli, E | 1 |
| Muratore, F | 1 |
| Boiardi, L | 1 |
| Pipitone, N | 1 |
| Cassone, G | 1 |
| Croci, S | 1 |
| Marata, AM | 1 |
| Costantini, M | 1 |
| Giorgi Rossi, P | 1 |
| McLean, ARD | 1 |
| Boel, M | 1 |
| McGready, R | 1 |
| Ataide, R | 1 |
| Drew, D | 1 |
| Tsuboi, T | 1 |
| Beeson, JG | 1 |
| Nosten, F | 1 |
| Simpson, JA | 1 |
| Fowkes, FJI | 1 |
| SWARTZWELDER, JC | 1 |
| MULE, JG | 1 |
| FRYE, WW | 1 |
| VELLA, F | 1 |
| Khan, MA | 1 |
| Jabeen, R | 1 |
| Mohammad, O | 1 |
| Hatabu, T | 1 |
| Kawazu, S | 1 |
| Kojima, S | 1 |
| Sato, K | 1 |
| Singhasivanon, P | 1 |
| Looareesuwan, S | 1 |
| Kano, S | 1 |
| Zipris, D | 1 |
| Lien, E | 1 |
| Nair, A | 1 |
| Xie, JX | 1 |
| Greiner, DL | 1 |
| Mordes, JP | 1 |
| Rossini, AA | 1 |
| Stokes, WS | 1 |
| Donovan, JC | 1 |
| Montrey, RD | 1 |
| Thompson, WL | 1 |
| Wannemacher, RW | 1 |
| Rozmiarek, H | 1 |
| Blasi, E | 1 |
| Barluzzi, R | 1 |
| Mazzolla, R | 1 |
| Bistoni, F | 1 |
| Fryauff, DJ | 1 |
| Baird, JK | 1 |
| Awalludin, M | 1 |
| Jones, T | 1 |
| Subianto, B | 1 |
| Richie, TL | 1 |
| Tjitra, E | 1 |
| Wignall, FS | 1 |
| Hoffman, SL | 1 |
| Collins, WE | 1 |
| Skinner, JC | 1 |
| Broderson, JR | 1 |
| Filipski, VK | 1 |
| Morris, CM | 1 |
| Stanfill, PS | 1 |
| Warren, M | 1 |
| Vespa, L | 1 |
| Zwilling, BS | 1 |
1 review available for chloroquine and Diathesis
| Article | Year |
|---|---|
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Me | 2020 |
1 trial available for chloroquine and Diathesis
| Article | Year |
|---|---|
Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis.
Topics: Antimalarials; Chloroquine; Disease Susceptibility; Follow-Up Studies; Humans; Incidence; Indonesia; | 1997 |
12 other studies available for chloroquine and Diathesis
| Article | Year |
|---|---|
Bacillus Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.
Topics: Aging; Antiviral Agents; BCG Vaccine; Chemoprevention; Chloroquine; Coronavirus Infections; COVID-19 | 2020 |
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, | 2021 |
Antibody Responses to
Topics: Adaptive Immunity; Antibodies, Protozoan; Antimalarials; Artemisinins; Artesunate; Chloroquine; Coho | 2017 |
Trichomonas vaginalis infection; evaluation of the susceptibility to systemic medication.
Topics: Chloroquine; Disease; Disease Susceptibility; Female; Humans; Trichomonas Infections; Trichomonas va | 1955 |
The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy.
Topics: Africa, Eastern; Amodiaquine; Antimalarials; Chloroquine; Disease Susceptibility; Drug Combinations; | 2003 |
Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole.
Topics: Animals; Cell Line; Chloroquine; Cryptococcosis; Cryptococcus neoformans; Disease Models, Animal; Di | 2004 |
In vitro susceptibility and genetic variations for chloroquine and mefloquine in Plasmodium falciparum isolates from Thai-Myanmar border.
Topics: Animals; Chloroquine; Disease Susceptibility; Drug Resistance, Microbial; Genetic Variation; Humans; | 2005 |
TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat.
Topics: Animals; B-Lymphocytes; Breeding; Cells, Cultured; Chloroquine; Diabetes Mellitus, Type 1; Disease S | 2007 |
Acute clinical malaria (Plasmodium inui) in a cynomolgus monkey (Macaca fascicularis).
Topics: Acute Disease; Animal Population Groups; Animals; Animals, Wild; Antimalarials; Chloroquine; Disease | 1983 |
Differential host susceptibility to intracerebral infections with Candida albicans and Cryptococcus neoformans.
Topics: Animals; Brain Diseases; Candidiasis; Chloroquine; Colchicine; Cryptococcosis; Disease Susceptibilit | 1993 |
Susceptibility of Macaca fascicularis monkeys from Mauritius to different species of Plasmodium.
Topics: Animals; Chloroquine; Disease Susceptibility; Drug Therapy, Combination; Macaca fascicularis; Malari | 1992 |
Expression of I-A by macrophages from Bcgr and Bcgs mice. Transient expression of I-A is due to degradation of MHC class II glycoproteins.
Topics: Animals; Chloroquine; Disease Susceptibility; Glycoproteins; Histocompatibility Antigens Class II; I | 1989 |